Simplify Logo

Internship

Spring 2025 Co-op: AAV Biology

Confirmed live in the last 24 hours

Prime Medicine

Prime Medicine

201-500 employees

Gene editing technology for genetic diseases

Biotechnology
Healthcare

Cambridge, MA, USA

Candidates must be from the local Boston/Cambridge area.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Direct experience working in a laboratory setting and demonstrated ability to perform routine laboratory procedures.
  • Experience conducting experiments, collecting and analyzing experimental data, and presenting results to the larger team.
  • Rigorous and conscientious, exhibiting care and thoroughness in experiment execution and data interpretation.
  • Motivation and passion for driving effective gene editing therapeutic to patients.
  • B.S. or M.S. candidate in Cell & Molecular Biology or related major.
  • Effective communication skills, with the ability to describe research clearly and concisely to a cross-disciplinary audience
  • Goal-driven, with strong organizational skills, including record keeping, documentation, and reporting of research.
  • Highly adaptable and comfortable in an environment with dynamic priority demands.
  • Ability to work independently and within a team
Responsibilities
  • Assist the team with AAV production and quality characterization utilizing basic aseptic cell culture technique, ddPCR, SDS PAGE, Silver Staining, denaturing gel electrophoresis, and other relevant techniques and assays.
  • Contribute to the team’s efforts to characterize and optimize Prime’s AAV delivery platform with a variety of molecular and cell biology activities to include DNA and RNA purification, common cloning methods (eg. Gibson assembly), NGS sample preparation, qPCR, etc.
  • Assist with experimental design and conduct experiments to characterize newly designed vectors and impact on efficacy and safety.
  • Contribute to the scientific discussions and output of the team
  • Collect and analyze experimental data, compile experimental summaries in an Electronic Lab Notebook (ELN), and present results to the larger team
  • Adhere to all laboratory safety requirements and procedures

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, Prime Medicine collaborates with research institutions and pharmaceutical companies to advance its technology and generate revenue through licensing and partnerships. The leadership team, including experienced professionals like Chief Technical Officer Ann L. Lee, is dedicated to enhancing the company's technological capabilities and expanding operations.

Company Stage

N/A

Total Funding

$596M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

3%

1 year growth

6%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $161 million PIPE offering and previous substantial funding rounds indicate strong investor confidence and financial stability.
  • Partnerships with organizations like the Cystic Fibrosis Foundation provide both financial support and validation of Prime Medicine's technology.
  • Successful preclinical data in non-human primates demonstrate the potential efficacy and safety of Prime Editing, bolstering the company's scientific credibility.

What critics are saying

  • The highly competitive biotech landscape requires continuous innovation to maintain a leading position.
  • Regulatory hurdles and the complexity of clinical trials could delay the commercialization of Prime Editing therapies.

What makes Prime Medicine unique

  • Prime Medicine's Prime Editing technology offers unparalleled precision in DNA modification, setting it apart from other gene-editing techniques like CRISPR.
  • The company's focus on developing one-time curative therapies for genetic diseases provides a unique value proposition in the biotech sector.
  • Strategic collaborations with research institutions and pharmaceutical companies enhance Prime Medicine's ability to innovate and bring its technology to market.